Movement Alert｜DUALITYBIO-B Rises 5.28% in Regular Trading, Biotech Sector Rally Extends Valuation Recovery

Market Focus08-11

On August 11, DUALITYBIO-B rose 5.28% in regular trading, trading at 207.6 HKD/share, with turnover of approximately 106 million HKD. The stock continued its rebound driven by broad-based strength across the biotechnology sector.

The rally was primarily fueled by a collective surge in biotech peers, with BeiGene up 4.41%, Zai Lab up 4.6%, and Akeso up 2.76%, reflecting sustained sector sentiment recovery. DUALITYBIO-B had previously dropped sharply on July 30 due to competitive pressure from GSK in its core ADC pipeline, and has since been gradually stabilizing and recovering.

Supporting the recovery, the company's fundamentals remain underpinned by multiple catalysts: its B7-H3 ADC received NMPA Breakthrough Therapy Designation, its Science and Technology Innovation Board (STAR Market) IPO application has entered the inquiry stage at the Shanghai Stock Exchange, and multiple brokerages have initiated coverage with Buy ratings and target prices significantly above current levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113058527?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 11:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113058527","market":"us","top_or_hot":-1,"title":"Movement Alert｜DUALITYBIO-B Rises 5.28% in Regular Trading, Biotech Sector Rally Extends Valuation Recovery","media":"Market Focus","content":"<p><p>On August 11, DUALITYBIO-B rose 5.28% in regular trading, trading at 207.6 HKD/share, with turnover of approximately 106 million HKD. The stock continued its rebound driven by broad-based strength across the biotechnology sector.</p><p>The rally was primarily fueled by a collective surge in biotech peers, with BeiGene up 4.41%, Zai Lab up 4.6%, and Akeso up 2.76%, reflecting sustained sector sentiment recovery. DUALITYBIO-B had previously dropped sharply on July 30 due to competitive pressure from GSK in its core ADC pipeline, and has since been gradually stabilizing and recovering.</p><p>Supporting the recovery, the company's fundamentals remain underpinned by multiple catalysts: its B7-H3 ADC received NMPA Breakthrough Therapy Designation, its Science and Technology Innovation Board (STAR Market) IPO application has entered the inquiry stage at the Shanghai Stock Exchange, and multiple brokerages have initiated coverage with Buy ratings and target prices significantly above current levels.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DUALITYBIO-B Rises 5.28% in Regular Trading, Biotech Sector Rally Extends Valuation Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DUALITYBIO-B Rises 5.28% in Regular Trading, Biotech Sector Rally Extends Valuation Recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-11 11:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 11, DUALITYBIO-B rose 5.28% in regular trading, trading at 207.6 HKD/share, with turnover of approximately 106 million HKD. The stock continued its rebound driven by broad-based strength across the biotechnology sector.</p><p>The rally was primarily fueled by a collective surge in biotech peers, with BeiGene up 4.41%, Zai Lab up 4.6%, and Akeso up 2.76%, reflecting sustained sector sentiment recovery. DUALITYBIO-B had previously dropped sharply on July 30 due to competitive pressure from GSK in its core ADC pipeline, and has since been gradually stabilizing and recovering.</p><p>Supporting the recovery, the company's fundamentals remain underpinned by multiple catalysts: its B7-H3 ADC received NMPA Breakthrough Therapy Designation, its Science and Technology Innovation Board (STAR Market) IPO application has entered the inquiry stage at the Shanghai Stock Exchange, and multiple brokerages have initiated coverage with Buy ratings and target prices significantly above current levels.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1113058527","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113058527","pubTimestamp":1786420387,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 11, DUALITYBIO-B rose 5.28% in regular trading, trading at 207.6 HKD/share, with turnover of approximately 106 million HKD. The stock continued its rebound driven by broad-based strength...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"走势提醒|DUALITYBIO-B 常规交易上涨 5.28%，生物技术板块反弹延续估值复苏","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On August 11, DUALITYBIO-B rose 5.28% in regular trading, trading at 207.6 HKD/share, with turnover of approximately 106 million HKD. The stock continued its rebound driven by broad-based strength across the biotechnology sector.The rally was primarily fueled by a collective surge in biotech peers, with BeiGene up 4.41%, Zai Lab up 4.6%, and Akeso up 2.76%, reflecting sustained sector sentiment recovery. DUALITYBIO-B had previously dropped sharply on July 30 due to competitive pressure from GSK in its core ADC pipeline, and has since been gradually stabilizing and recovering.Supporting the recovery, the company's fundamentals remain underpinned by multiple catalysts: its B7-H3 ADC received NMPA Breakthrough Therapy Designation, its Science and Technology Innovation Board (STAR Market) IPO application has entered the inquiry stage at the Shanghai Stock Exchange, and multiple brokerages have initiated coverage with Buy ratings and target prices significantly above current levels.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113058527","isCrawlerRequest":true}